Endoscopic Gastric Plication for Morbid Obesity: a Systematic Review and Meta-analysis of Published Data over Time
- 345 Downloads
Endoscopic gastric plication or gastroplasty for morbid obesity is gaining worldwide recognition. Data concerning safety and efficacy are rather scarce. Furthermore, clear guidelines are yet to be established. The objective of this meta-analysis is to update the data and investigate the efficacy and safety of the procedure. An online comprehensive search using Cochrane, Google Scholar, PubMed, Web of Science, and Embase on endoscopic gastric plication was completed. The primary outcome was defined as weight loss at 6 months or more after the procedure. Secondary outcomes were defined as the occurrence of adverse events or complications including insufficient weight loss or regain. I2 statistic was used to define the heterogeneity across studies. Twenty-two cohort studies on 7 different devices met the inclusion criteria, with a total of 2475 patients. The mean baseline BMI was 37.8 ± 4.1 kg/m2 (median 37.9; range 28.0–60.2). Either a transoral endoluminal stapling or (suction based) (full-thickness) stitching and/or anchor device was used to obtain gastric volume reduction and/or alter gastric outlet. The mean follow-up was 13 months (median 12; range 6–24) for the specified outcomes of each study. Two active, FDA-approved devices were taken into account for meta-analysis: Endoscopic sleeve gastroplasty (ESG) and the primary obesity surgery endolumenal (POSE™). Average pooled %EWL at 6 months (p = 0.02) and 12 months (p = 0.04) in favor of ESG was 57.9 ± 3.8% (50.5–65.5, I2 = 0.0), 44.4 ± 2.1% (40.2–48.5, I2 = 0.0), and 68.3 ± 3.8% (60.9–75.7, I2 = 5.8), 44.9 ± 2.1% (40.9–49.0, I2 = N/A) for ESG and POSE respectively. Major adverse events without mortality were described in 25 patients (9 studies, p = 0.63). ESG and POSE are both safe and feasible procedures with good short-term weight loss. ESG seems to be superior in terms of weight loss at this point. Few major adverse events are reported and long-term results are awaited.
KeywordsEndoscopic Sleeve Gastroplasty Bariatric Remodeling Meta-analysis Review ESG Pose
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 1.018 WHO fact sheets obesity and overweight. http://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight
- 16.Lopez-Nava G, Galvão MP, Bautista-Castaño 1 d, et al. Endoscopic sleeve gastroplasty for the treatment of obesity. Endoscopy. 2015;47(5):449–52.Google Scholar
- 20.Alqahtani A, Al-Darwish A, Mahmoud AE et al. Short-term outcomes of endoscopic sleeve gastroplasty in 1000 consecutive patients. Gastrointest Endosc 2018 . pii: S0016-5107(18)33363-7.Google Scholar
- 29.Seeras K, Prakash S. Laparoscopic Lap Band Placement. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan–2018 Jul 29.Google Scholar
- 32.Khan Z, Khan MA, Hajifathalian K, et al. Efficacy of endoscopic interventions for the management of obesity: a meta-analysis to compare endoscopic sleeve gastroplasty, AspireAssist, and primary obesity surgery endolumenal. Obes Surg. 2019;29:2287–98. https://doi.org/10.1007/s11695-019-03865-w.CrossRefPubMedPubMedCentralGoogle Scholar